INM — InMed Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $5.46m
- -$5.66m
- $4.94m
- 35
- 65
- 32
- 40
Annual income statement for InMed Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.09 | 4.14 | 4.6 | 4.94 |
| Cost of Revenue | |||||
| Gross Profit | — | 0.544 | 1.4 | 1.1 | 1.71 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.94 | 18.4 | 12.5 | 12.8 | 12.9 |
| Operating Profit | -9.94 | -17.3 | -8.38 | -8.2 | -7.95 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.2 | -18.6 | -7.93 | -7.67 | -8.16 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.2 | -18.6 | -7.95 | -7.68 | -8.16 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.2 | -18.6 | -7.95 | -7.68 | -8.16 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.2 | -18.6 | -7.95 | -7.68 | -8.16 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -759 | -532 | -64.9 | -20.1 | -8.36 |